Baqsimi

Active Ingredient(s): Glucagon
FDA Approved: * July 24, 2019
Pharm Company: * ELI LILLY AND CO
Category: Hypoglycemia

1BH0, 1NAU, 2G49, 2M5P, 2M5Q,%%s4ZGM, 4APD, 3IOL, 1D0R,%%s2L64, 2L63IdentifiersAliasesGCG, GLP1, glucagon, GRPP, GLP-1, GLP2External IDsOMIM: 138030 HomoloGene: 136497 GeneCards: GCG Gene location (Human)Chr.Chromosome 2 (human)[1]Band2q24.2Start162,142,882 bp[1]End162,152,404 bp[1]RNA expression patternBgeeTop expressed in islet of Langerhans duodenum pancreas Body of pancreas rectum sigmoid colon organ system colonMore reference expression da... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Baqsimi 3 mg Nasal Powder
NDC: 0002-6145
Labeler:
Eli Lilly and Company
Baqsimi 3 mg Nasal Powder
NDC: 0548-8351
Labeler:
Amphastar Pharmaceuticals, Inc.
Baqsimi 3 mg Nasal Powder
NDC: 0548-8352
Labeler:
Amphastar Pharmaceuticals, Inc.

Related Brands

Drugs with the same active ingredients